Triodos Bank N.V. (TRIO)
Euronext Amsterdam · Netherlands · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 34.00 |
|---|---|
| 52-week range | 26.30 – 42.15 |
| Return, 1 month / 3 months | −12.4% / +25.5% |
| Return, 1 year / 3 years | +24.1% / – |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 32 |
| Volatility (1 year) | 27.5% |
| Worst drawdown (1 year) | -17.3% |
| Average daily value traded | 0.99M EUR |
| Dividend yield | 3.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Triodos Bank is a bank based in the Netherlands that focuses on sustainable and ethical finance. It provides savings accounts, payment accounts and lending to individuals, businesses and organisations, and it finances projects in areas such as renewable energy, organic farming, culture and social enterprise. Its customers include savers and borrowers who want their money used for environmental and social purposes, and it also offers investment funds that follow the same approach.
The shares are listed on the Euronext Amsterdam in Netherlands under the code TRIO, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 2 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Triodos Bank N.V. (TRIO) trades on the Euronext Amsterdam in Netherlands. It last closed at EUR 34.00 on 23 October 2026.
Its price-based Market X-Ray is 67 out of 100 (a fair price profile), ranking 24 of 109 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 24.1% and over the last three months it rose 25.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Amsterdam
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 76 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 13.2% | ||
| From 52-week high | -17.3% | ||
| Momentum | 87 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 25.5% | ||
| 6-month return | 25.1% | ||
| 12-month return, skipping the last month | 41.7% | ||
| Stability (higher is calmer) | 68 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 27.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -17.3% | ||
| Liquidity | 44 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.99M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 23 · Weak | Dividend is small or irregular. | |
| Dividend yield | 3.1% | ||
| Years with dividends | 2 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | −4.2% |
|---|---|
| 1 month | −12.4% |
| 3 months | +25.5% |
| 6 months | +25.1% |
| 1 year | +24.1% |
| 3 years | – |
| 5 years | – |
Signals
| 50-day / 200-day average | 36.74 / 30.05 |
|---|---|
| Golden / death cross (60 days) | Golden, 47 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.92 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 17 Aug 2026 | EUR 1.0500 |
| 18 Aug 2025 | EUR 0.6000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Amsterdam; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.